Lancashire and South Cumbria
Formulary
Formulary
10 Musculoskeletal and joint diseases
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
10-02-02 Skeletal muscle relaxants
| Cannabis extract Sativex® |
|
Formulary
|
Oromucosal spray cannabidiol 2.5mg per dose, Dronabinol 2.7mg per dose
|
 NICE NG144: Cannabis-based medicinal products |
|
for Refractory neuropathic pain.| Diazepam |
|
Formulary
|
Tablets 2mg, 5mg, 10mg |
|
MHRA: Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression |
|
| Mexiletine hydrochloride Namuscla® |
|
Formulary
|
Capsules 167mg |
|
NICE TA748: Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders |
|
Links
- Cochrane review of the evidence
EMSCG Commissioning policy for Intrathecal Baclofen (ITB)- LSCMMG: Inflammatory Bowel Disease: High Cost Drugs Commissioning Pathway
- LSCMMG: Primary Care Constipation Guidelines
- MHRA Drug Safety Update Nov 2017: Quinine: reminder of dose-dependent QT-prolonging effects; updated medicine interactions
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression
- MHRA: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration
- MHRA: Nusinersen (Spinraza▼): reports of communicating hydrocephalus; discuss symptoms with patients and carers and investigate urgently
- MHRA: Quinine: not to be used routinely for nocturnal leg cramps
- MHRA: Quinine: reminder of dose-dependent QT-prolonging effects; updated medicine interactions
- NHSE: Steroid Emergency Card to support early recognition and treatment of adrenal crisis in adults
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE HST15: Onasemnogene abeparvovec for treating spinal muscular atrophy
- NICE HST15: Onasemnogene abeparvovec for treating spinal muscular atrophy
- NICE HST22:Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene
- NICE HST24: Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy
- NICE HST24: Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE NG144: Cannabis-based medicinal products
- NICE NG144:Cannabis-based medicinal products
- NICE NST22 Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene
- NICE TA1031: Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over
- NICE TA588: Nusinersen for treating spinal muscular atrophy
- NICE TA588: Nusinersen for treating spinal muscular atrophy
- NICE TA748: Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders
- NICE TA748: Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders
- NICE TA755: Risdiplam for treating spinal muscular atrophy
- NICE TA755:Risdiplam for treating spinal muscular atrophy